What You Should Know:
- McKesson has unveiled the Precision Care Companion (PCC), a transformative initiative designed to tackle the multifaceted challenges that healthcare practices face in the rapidly evolving landscape of genomic testing and targeted therapies.
- The Precision Care Companion is structured as a consortium of leading industry experts, spearheaded by McKesson. This collaborative model is intentionally designed to foster a dynamic environment that unites a diverse
Read More
Biomarkers| Big Data| News, Analysis, Insights - HIT Consultant
Quibim Secures $50M to Advance AI-Powered Imaging Biomarkers for Precision Medicine
What You Should Know:
- Quibim, a leading healthtech company pioneering the use of imaging biomarkers for precision medicine, announced today the close of its $50 million Series A financing.
- The company has experienced remarkable growth in the number of patients analyzed by its products over the past year. Driven by several regulatory approvals and global commercial partnerships, patient analysis surged by 168% quarter-on-quarter.
Quibim: Advancing Precision Medicine Through
Read More
5 Vocal Biomarker Trends to Watch in 2025
In recent years, the use of AI-enhanced ambient listening tools has transformed the way clinicians utilize vocal biomarkers for cognitive and behavioral health assessments. As these technologies expand, clinicians are exploring use-cases for a wider range of languages, populations, and more conditions as well. Looking ahead to 2025, expect vocal biomarkers to play a more essential role in disease detection, offering valuable insights while saving time for both
Read More
Proscia and Nucleai Partner to Integrate Predictive Biomarker Solutions
What You Should Know:
- Proscia, a leader in artificial intelligence (AI)-powered pathology solutions, and Nucleai, a leading spatial AI biomarker company, announced a strategic partnership today. This collaboration aims to revolutionize precision medicine by integrating Nucleai's advanced biomarker technology with Proscia's Concentriq® software platform.
- By harnessing the power of AI and digital pathology, this partnership offers the potential to fundamentally improve the
Read More
Nucleai, GoPath Diagnostics Partner to Power AI-Powered Digital Pathology
What You Should Know:
- Nucleai, a leader in spatial biology and AI, and GoPath Diagnostics, a leading provider of digital pathology and molecular diagnostics, announced a strategic collaboration today.
- The partnership aims to revolutionize clinical trials, diagnostics, and research in oncology and immunology by combining their strengths in AI and real-world data.
Unlocking the Power of Spatial AI Biomarkers
Nucleai specializes in "spatial AI biomarkers." This
Read More
Detect Depression in Seconds Wellin5 x Kintsugi Voice Biomarker Integration
What You Should Know:
Wellin5, the premier provider of online counseling, proudly announces a new partnership with Kintsugi, an AI mental health technology leader.This collaboration comes at a time when Wellin5 has successfully navigated the turbulent economic landscape and challenges in the health tech space to thrive and bring this vital partnership to life, setting a new standard in mental health care for over 50,000 clients based in Canada and the USA.
Revolutionizing
Read More
Debiopharm and ThinkingNodeLife.ai Partner on AI-Driven Cancer Drug Development
What You Should Know:
- Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.
- This strategic partnership combines Debiopharm's deep pharmaceutical expertise with TNL's revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.
Unlocking the Hidden Potential of a
Read More
23andMe Launches Health Action Plan Based on Genetic/Health Data
What You Should Know:
- 23andMe, a genetic health and biopharmaceutical company launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options.
- Health Action Plan is a helpful first step when it comes to prevention and early risk detection. It offers customers specific actions and
Read More
The Future of Biomarker-Based Therapy for Mental Disorder Care
We are living in a mental health epidemic. An estimated 26 percent of Americans ages 18 and older – about one in four adults – suffer from a diagnosable mental disorder in a given year. Among mental disorders, cases of PTSD are on the rise. Roughly five percent of American adults suffer from PTSD in any given year and more than 13 million Americans reported PTSD in 2020 – most of whom are women. Standard PTSD treatments most often come in the form of pharmacotherapy or psychotherapy and include
Read More
Mount Sinai Researchers Identify Biomarker That Tracks Recovery From Treatment-Resistant Depression
What You Should Know:
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More
